icon

Breast Cancer Risk Assessment Report

reports

Published: 01 January 1970, 12:00pm

Breast Cancer Risk Assessment - GP report

Report ID

#

NHI

Date of birth

01 Jan 1970

iconGeneral information

BRRISK is a validated risk model (using BOADICEA developed by University of Cambridge, Department of Public and Primary Care) to stratify risk of breast cancer.

Stratification into population, moderate or high risk helps you to triage patients into the right surveillance pathway and determining who to refer to specialists either in Private or Public.

This is an objective assessment. Patients enter their information into a web-based application, which is intuitive and friendly to use, so they can present you with a report for your consult.

Further information about BRRISK can be found here brrisk.co/about-brrisk (URL to be finalised)


Your patient has completed a BRRISK breast cancer risk assessment

The BRRISK assessment confirms

  • 0.00% in the next 5 years
  • 0.00% in the next 10 years
  • 0.00% from current age to age 80
graph

Your patients lifetime risk from age 20 of having breast cancer is 0.00%. According to the eviQ guidelines they would be in the Population risk category.

Your patients risk between ages 40 and 50 of having breast cancer is 0.00%. According to the eviQ guidelines they would be in the Population risk category.

Guidance

International guidelines providing the risk management strategies.

Near population risk Moderate risk High risk
Lifetime risk from age 20 Less than 17% 17% or greater but less than 30% 30% or greater
Risk between ages 40 and 50 Less than 3% 3% or greater to 8% Greater than 8%
 

The following information is provided as a guide only and is based on eviQ guidelines. Clinical decisions are always between the women and her GP / Specialist.

The impact of lifestyle on cancer risk should be discussed e.g.exercise regularly, maintain healthy weight, have a healthy diet, limit alcohol intake, do not smoke, avoid excessive sun exposure and minimise exogenous estrogen and progesterone exposure


Population Risk

Women with this level of risk are considered to be at population risk of breast cancer.


Moderate Risk

Higher than 17% but lower than 30% lifetime risk

Women with this level of risk are considered to have a “moderately increased” risk of breast cancer when compared to the general population.

Surgical
Risk-reducing mastectomy is not recommended.
Surveillance
Age Strategy and Frequency
All ages Breast awareness with prompt reporting to general practitioner of persistent or unusual changes
Between 40 to 50 years Recommended yearly mammograms
Between 50 to 59 years Offer mammograms 2 yearly. Consider yearly in women with additional risk factors
From 60 years Recommended mammograms every 2 years
Risk reducing medication
  • Consider use of medication, such as tamoxifen or raloxifene to reduce risk of developing breast cancer
  • Requires assessment of risks and benefits for an individual woman by an experienced medical professional. See COSA -Medications to lower the risk of breast cancer: clinician guide

High Risk

Higher than 30% lifetime risk (or > 8% between 40 and 50 years)

Women with this level of risk are considered to be significantly higher when compared to the general population.

Surgical
Discuss bilateral risk reducing mastectomy
Surveillance
Age Strategy and Frequency
< 40 years
  • Assess 10-year breast cancer risk using a validated risk model such as BRRISK (BOADICEA) and determine commencement age for screening based on personalised risk by age
  • Recommend annual breast MRI +/- mammography if screening advised
> 40 years Recommend annual breast MRI until at least age 50 (and longer if dense breasts) + annual mammography (digital, consider tomosynthesis where possible)
Risk reducing medication
Discuss risk reducing medication